Osprey makes successful landing on ASX

Osprey Medical ($OSP) has reportedly caught the eye of investors with an auspicious beginning in its first day trading on the Australian Securities Exchange (ASX). It made its debut with a 5% premium listing at 42 cents, 2 cents above its issue price, The Australian notes. The news comes a month after the company announced that it had raised $20 million Australian ($20.8 million) in its IPO. "With the success of the IPO, we are now very strongly placed for our pivotal clinical trial in the U.S. and the commercialization of the CINCOR system, initially in Germany and the Netherlands," said Mike McCormick, Osprey president and CEO. The CINCOR system is designed to guard against contrast induced nephropathy, a type of kidney damage, in high-risk patients undergoing certain heart procedures. Osprey release | More

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.